Structural and Molecular Neuroplasticity in Migraine

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03004313

Enrollment

Registered

2016-12-28

Start date

2011-01-31

Completion date

2014-10-31

Last updated

2017-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Keywords

migraine

Brief summary

The main purpose of this study is to integrate novel MRI techniques with positron emission tomography(PET) for the study of structural and molecular neuroplasticity in the brain of migraineurs, and its clinical association with changes in pain perception and modulation (e.g. allodynia). We will attempt to acquire images of the brain that may, in the future, assist doctors in better understanding how pain is felt and regulated in migraine sufferers.

Detailed description

To investigate interictal opioid receptor (MOR) binding potential (BPND) changes in migraineurs as compared to age/gender-matched healthy controls. To demonstrate that frequency of the headache attacks and severity of cutaneous allodynia levels in migraineurs experienced over multiple attacks are correlated with levels of MOR BPND in specific brain regions. To investigate whether dysfunction of the pain regulatory endogenous opioid system of migraineurs is correlated with changes in the gray matter thickness in cortical areas associated with pain perception and modulation.

Interventions

PROCEDUREPet Scan

Subjects will undergo Pet Scanning for 90 minutes

PROCEDUREMRI scan

PROCEDUREQuantitative Sensory Testing (QST)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Between 18-45 years of age * Between 1-14 migraine attacks per month or healthy

Exclusion criteria

* Cannot be taking daily migraine medication * Healthy subjects cannot be taking hormonal birth control pills or other medication * Cannot have chronic pain or a neurologic/psychiatric disorder such as: multiple sclerosis and bipolar disorder.

Design outcomes

Primary

Measure	Time frame
Level of mu-opioid receptor binding potential in the brain of episodic migraineurs during and outside the headache attack and compared to healthy controls.	90 min PET scan

Secondary

Measure	Time frame
Correlation of migraine attack severity in migraineurs with mu-opioid receptor binding potential	90 min PET scan

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026